Epinephrine (generic), Epipen Newswire (Page 5)

Epinephrine (generic), Epipen Newswire (Page 5)

Comprehensive Real-Time News Feed for Epinephrine (generic), Epipen. (Page 5)

Results 81 - 100 of 3,299 in Epinephrine (generic), Epipen

  1. 'She started convulsing': Hero husband carries wife through croc-inhabited watersRead the original story w/Photo

    Mar 9, 2017 | ABC News

    A Darwin couple has revealed an ordeal that saw them wade through crocodile-inhabited waters to be airlifted to hospital, when the woman fell unconscious after being bitten by a March fly. Husband and wife, Allan and Zerena Di-Prima, told ABC Tales from the Tinny how a typical day of fishing in Leaders Creek, about six weeks ago, took a dramatic turn after they became marooned by a low tide.

    Comment?

  2. Head to Head Analysis: NephroGenexRead the original story w/Photo

    Dec 8, 2017 | AmericanBankingNews.com

    NephroGenex and Mylan are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability. Mylan has higher revenue and earnings than NephroGenex.

    Comment?

  3. NephroGenex (NRXGQ) and Mylan (MYL) Financial SurveyRead the original story w/Photo

    Dec 7, 2017 | AmericanBankingNews.com

    NephroGenex and Mylan are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk. NephroGenex presently has a consensus price target of $17.50, suggesting a potential upside of 624,900.00%.

    Comment?

  4. Reviewing Adamis Pharmaceuticals (ADMP) & Its CompetitorsRead the original story w/Photo

    Dec 7, 2017 | IntersportsWire

    Adamis Pharmaceuticals is one of 103 public companies in the "Pharmaceuticals" industry, but how does it compare to its peers? We will compare Adamis Pharmaceuticals to related companies based on the strength of its earnings, valuation, dividends, institutional ownership, profitability, risk and analyst recommendations. 16.7% of Adamis Pharmaceuticals shares are owned by institutional investors.

    Comment?

  5. EPINEPHrine for Anaphylaxis: Autoinjector or 1-mg Vial or Ampoule?Read the original story

    Dec 7, 2017 | P&T Community

    Anaphylaxis is a medical emergency that requires immediate treatment with EPINEPHrine injection. The condition is becoming more common outside of the hospital due to increases in food allergies and the use of contrast media, chemotherapy, and monoclonal antibodies in outpatient clinics.

    Comment?

  6. Maryland to receive $10M from EpiPen maker Mylan in Medicaid fraud settlementRead the original story w/Photo

    Dec 7, 2017 | The Baltimore Sun

    The state of Maryland will receive nearly $10 million from Epipen maker Mylan, part of the companmy's $465 million settlement with the Department of Justice over allegations that it overbilled Medicaid for the life-saving allergy medication injections, Maryland Attorney General Brian Frosh announced Thursday. The settlement resolved allegations that Mylan improperly classified EpiPens, a brand-name drug, as a generic medication between 2010 and 2016 to avoid paying higher rebates on the epinephrine-filled devices - overcharging state Medicaid programs while raising the price of the medication in the private market.

    Comment?

  7. INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for AnaphylaxisRead the original story

    Dec 7, 2017 | Customer Interaction Solutions

    INSYS Therapeutics, Inc. , announced today that it has started a proof-of-concept study of two formulations of epinephrine nasal spray for the treatment of anaphylaxis, or severe allergic reaction, with the enrollment of the first patient. This Phase 1 clinical trial is designed to establish whether intranasal administration of epinephrine is bioequivalent to the standard method of delivering the drug, which is through intramuscular injection .

    Comment?

  8. Watch These December Biotech CatalystsRead the original story w/Photo

    Dec 5, 2017 | Seeking Alpha

    December brings a number of important catalysts for companies in the biotech sector, which have the potential to move these stocks significantly before year-end. Heron Therapeuticsgets an honorable mention, thanks to jumping the gun and announcing a dilution beforeI could get this article finished.

    Comment?

  9. Is Your Teen Taking Risks With Their Food Allergies?Read the original story w/Photo

    Dec 5, 2017 | CBS Local

    CBS 3 CBS 3 joined forces with the most trusted local CBS RADIO stations in Philadelphia to give you the best Philly has to offer. CBS 3 is part of CBS Television Stations, a division of CBS [] KYW Newsradio 1060 Traffic.

    Comment?

  10. Adamis Pharmaceuticals Announces Submission of Investigational New...Read the original story

    Dec 4, 2017 | Customer Interaction Solutions

    Adamis Pharmaceuticals Corporation announced that it has submitted an investigational new drug application to the U.S. Food and Drug Administration to begin testing the drug compound naloxone in human patients. Adamis intends to develop a naloxone injection product candidate utilizing the same patented SymjectTM syringe drug delivery platform used in Adamis' approved SymjepiTM product, which is an epinephrine injection drug/device combination for the emergency treatment of acute allergic reactions including anaphylaxis.

    Comment?

  11. Contrasting MylanRead the original story w/Photo

    Dec 4, 2017 | IntersportsWire

    Mylan and NephroGenex are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk. Mylan currently has a consensus target price of $40.96, indicating a potential upside of 7.45%.

    Comment?

  12. U.S. FDA wants more generic drug-device combosRead the original story w/Photo

    Dec 3, 2017 | Chemical & Engineering News

    U.S. Food & Drug Administration Commissioner Scott Gottlieb is continuing his push for cheaper drugs by making approvals of generics easier. FDA is committed to giving guidance on how companies can develop copycat products on complex drugs at least two years before the branded product's patent expires, Gottlieb said on Nov. 28. He spoke at FDA's Generic Drug Science Day in Silver Spring, Md.

    Comment?

  13. Financial Contrast: MylanRead the original story w/Photo

    Dec 3, 2017 | Daily Political

    Mylan and NephroGenex are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings. 73.9% of Mylan shares are owned by institutional investors.

    Comment?

  14. Head to Head Analysis: NephroGenexRead the original story w/Photo

    Dec 3, 2017 | Daily Political

    NephroGenex and Mylan are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. NephroGenex has a beta of -0.98, suggesting that its share price is 198% less volatile than the S&P 500.

    Comment?

  15. Adamis Pharmaceuticals (ADMP) vs. Its Peers Head to Head ReviewRead the original story w/Photo

    Dec 2, 2017 | AmericanBankingNews.com

    Adamis Pharmaceuticals is one of 104 publicly-traded companies in the "Pharmaceuticals" industry, but how does it weigh in compared to its rivals? We will compare Adamis Pharmaceuticals to similar companies based on the strength of its analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership. Adamis Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 146.91%.

    Comment?

  16. Financial Analysis: NephroGenexRead the original story w/Photo

    Dec 2, 2017 | The Breeze

    NephroGenex and Mylan are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends. Mylan has higher revenue and earnings than NephroGenex.

    Comment?

  17. Are EpiPens Friend or Foe?Read the original story w/Photo

    Dec 1, 2017 | JD Supra

    EpiPens exist to save lives or stave off severe allergic reactions to drugs, foods, insect bites and other causes of anaphylaxis. They are pocket-sized cylindrical devices that, in case of an episode, quickly can be uncapped and injected into the outer thigh for near-instant relief.

    Comment?

  18. Got food allergies? Add milk to the worries for your mealRead the original story w/Photo

    Dec 1, 2017 | The Baltimore Sun

    New research on food allergies finds that milk allergies pose not only a medical, but also a financial burden for families. New research on food allergies finds that milk allergies pose not only a medical, but also a financial burden for families.

    Comment?

  19. Adamis Pharmaceuticals Announces Presentation of Results of a Human...Read the original story w/Photo

    Dec 1, 2017 | GlobeNewswire

    Adamis Pharmaceuticals Corporation announced today the acceptance of a presentation entitled "Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe for the Emergency Treatment of Allergic Reactions Including Anaphylaxis". The presentation will be for the American Academy of Allergy, Asthma, and Immunology joint congress with the World Allergy Organization and will be held in Orlando, Florida on March 3, 2018.

    Comment?

  20. Mylan (MYL) versus NephroGenex (NRXGQ) Head-To-Head AnalysisRead the original story w/Photo

    Nov 30, 2017 | AmericanBankingNews.com

    Mylan and NephroGenex are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership. Mylan currently has a consensus target price of $40.96, indicating a potential upside of 11.12%.

    Comment?